The government’s internal inter-agency machinery does the heavy lifting before industry is invited in. That upstream process shapes, narrows and will almost certainly set the terms under which any negotiation involving the industry can take place. It still creates opportunity.
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News

